Beacon Rise Holdings PLC

29 September 2026

UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 JANUARY 2026 TO 30 JUNE 2026

Beacon Rise Holdings plc(LSE: BRS)has today published its unaudited condensed interim financial statements for the period from 1 January 2026 to 30 June 2026 (the "Interim Report").

In accordance with Listing Rule 9.6.1 copies of the Annual Report have been submitted to the UK Listing Authority and will shortly be available to view on the Company's website at https://www.beaconrise.uk/ and will be shortly available for inspection from the National Storage Mechanism at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

LEI: 2138007PIYMZMBWD4M27

Enquiries

For further information, please visit www.beaconrise.uk or contact Room 639, 6th Floor, 2 Kingdom Street, London, W2 6BD.

Company Registered number: 13620150 (England and Wales)

BEACON RISE HOLDINGS PLC

UNAUDITED CONDENSED INTERIM FINANCIAL STATEMENTS

FOR THE PERIOD FROM 1 JANUARY 2026 TO 30 JUNE 2026

Chairman's statement

I am pleased to present the unaudited condensed interim financial results for the Company for the six months ended 30 June 2026 ("H1 2026").

The principal activity of the Company is to acquire businesses in the primary and secondary segments of the healthcare sector with further interest in high end service sectors such as the healthcare education service sector.

To enable the Company to pursue its principal activities, the Company initiated an Initial Public Offering ("IPO") of its securities onto the London Stock Exchange (the "LSE") through a Standard Listing to raise the necessary funds required for the execution of the business strategy. The IPO was successfully completed, and the Company's shares were admitted to trading on the London Stock Exchange's Main Market on 25 March 2022. This listing enables the Company to raise funds for acquisitions which may be in the form of a merger, capital stock exchange, asset acquisition, stock purchase, scheme of the arrangement, reorganisation or similar business combination of an interest in an operating entity or investment.

The Company intends to delist from the LSE Main Market and list on the Alternative Investment Market (the "AIM" market) in the coming months, Advisors have been appointed, and the process is close to completion. As part of the listing process, the Company intends to make an acquisition of a Chiropractic practice in the Banbury area as the first in a programme of acquisitions.

As at the reporting period end, the Company did not have any current operations, no products were sold, and no services were performed by the Company. It did not operate or compete in any specific market, and the Company had no subsidiaries. The Company continues to seek acquisitions of UK and overseas businesses or assets with operations in the sectors that can contribute greater benefits to shareholders.

Strategy

The Company retains a flexible merge and acquisition strategy which will enable it to deploy capital in target companies by way of minority or majority investments, or full acquisitions where it is in the interests of shareholders to do so.

The Company's strategic aim is to drive shareholder value through the acquisition of target companies in certain sectors where the board of directors of the Company (the "Board" or the "Directors") believes there to be sustainable growth opportunities both organically, and through acquisition.

Financial results in the six months period ended 30 June 2026 Financial key performance indicators:

	6 months ended 30 June 2026 (Unaudited) £		6 months ended 30 June 2025 (Unaudited) £
EBITDA	(1,240,888)		(134,792)

	30 June 2026 (Unaudited)		30 June 2025 (Unaudited)
	£		£
Gross assets	115,160		190,836
Net (liabilities)/assets	(648,346)		151,811

Gender analysis

A split of our employees and directors by gender during the period is shown below:

                                                 Male                      Female
Directors                                           3                           0
As the Company is only in its infancy, gender of the Board is skewed towards males. This does not reflect the attitudes of the Company in any way, and the Directors intend to promote females to the Board as well as the workforce wherever possible. 

One of the Directors is from a minority ethnic background.

H1 2026 Review

During the first half of 2026, Beacon Rise Holdings plc continued to progress its strategy of developing from a listed acquisition platform into a healthcare and related services group with an operating base. As the Company has not yet completed its initial operating acquisition and does not currently benefit from recurring operating cash flows, the Board remained focused on transaction execution, capital discipline, governance and readiness for the transition to an operating group.

The principal areas of progress during the period are summarised below:

1. Governance and transaction readiness

The Company continued to strengthen its corporate, financial and governance framework in support of the proposed initial acquisition and the proposed cancellation of its Main Market listing and admission to AIM (the "AIM Admission"). Work during the period included the shareholder approvals, capital authorities, financial reporting and professional adviser coordination required to support the next stage of the Company's development. The Board has sought to ensure that governance, financing and transaction execution are considered as an integrated programme rather than as separate workstreams.

2. Disciplined acquisition strategy and transaction focus

The Board continued to apply a disciplined acquisition strategy, assessing opportunities by reference to business quality, valuation, transaction terms, risk-return characteristics, funding requirements and strategic fit. Following due diligence and commercial review, the Company elected not to progress opportunities that did not meet its investment criteria or support the interests of shareholders. This process resulted in a deliberate narrowing of the acquisition programme and the concentration of management, capital and adviser resources on one priority transaction. The Board considers this approach appropriate for establishing a sound basis for long-term shareholder value creation.

3. Financing capacity and liquidity discipline

From 1 January to 30 June 2026, the Company announced approximately £600,000 of gross fundraising through Advanced Subscription Agreements ("ASAs"), principally to support transaction costs, the proposed AIM Admission and working capital. One-off professional fees of £764,000 relating to preparations for the proposed AIM Admission were incurred during the six-month period ended 30 June 2026. These costs are non-recurring in nature and are not expected to recur at a similar level in subsequent periods. The ASAs enhanced the Company's financing capacity; however, the Board recognised that, as a pre-operating listed acquisition company, the Company remained exposed to liquidity pressure arising from listed-company costs, professional fees, transaction expenditure and the absence of recurring operating cash flow. Liquidity, cash forecasting and cost control therefore remained key areas of Board oversight.

4. Progress towards the initial acquisition and AIM Admission

The Company and its advisers continued the legal, financial, regulatory and documentation work required to progress the priority acquisition and the proposed AIM Admission. The Board has sought to coordinate transaction structure, due diligence, funding, regulatory requirements and completion planning so that the acquisition and the Company's capital-markets transition can progress on a coherent basis. Completion remains subject to satisfactory due diligence, funding, regulatory requirements and final documentation and terms.

5. Operating and integration readiness

In parallel with transaction work, management began preparing the capabilities required to oversee an operating business following completion. The focus has included financial reporting, management information, cash controls, internal controls, business continuity and practical digital capabilities. Digital development is being treated as an enabling capability for patient communication, service coordination and management oversight, rather than as a standalone business. The Company has also continued to deepen its understanding of healthcare and rehabilitation markets to support future investment judgement and post-acquisition management.

H2 2026 Strategic Priorities

For the second half of 2026, the Board intends to maintain a focused programme of execution. The priority is to progress the initial acquisition and AIM Admission while preserving sufficient financial and organisational capacity to support the Company through completion and into the early stages of operating ownership.

1. Progress the initial acquisition and AIM Admission

The Company will continue to concentrate its resources on progressing the priority transaction and the proposed AIM Admission. The Board and its advisers will continue work on due diligence, transaction documentation, financing and regulatory matters. Any transaction will remain subject to appropriate commercial terms, adequate funding, applicable regulatory requirements and the Board's assessment of the interests of shareholders.

2. Maintain financing flexibility and liquidity discipline

The Company will continue to assess its funding requirements against the timetable for the proposed acquisition, AIM Admission, professional costs and ongoing listed-company obligations. Following 30 June 2026, the Company raised a further £166,888 through ASAs, comprising approximately £50,000 announced on 13 July 2026, approximately £50,000 announced on 28 July 2026 and £66,888 announced on 1 September 2026. In addition, on 28 August 2026 the Company raised £58,131 through a direct equity issue. Accordingly, as at the date of this report, the Company had announced gross fundraising of approximately £825,019 since 1 January 2026, comprising approximately £766,888 through ASAs and £58,131 through the direct equity issue. Of the ASA investment, £500,000 had been completed through the issue of shares and £266,888 remained subject to completion. The Board will continue to pursue appropriate financing while maintaining disciplined cash management, budgeting and capital allocation.

3. Prepare for effective post-acquisition integration and operating oversight

The Company will continue to develop a proportionate integration framework covering financial reporting, management information, cash controls, internal controls, regulatory responsibilities, business continuity and digital support. The objective is to establish clear accountability and reliable management information from the outset, while minimising unnecessary disruption to the underlying operating business. Experience from the initial acquisition is expected to inform a more standardised and scalable approach to future integration.

4. Strengthen governance, Board capability and responsible business practices

As the Company moves towards operating ownership and the proposed AIM Admission, the Board will continue to strengthen governance arrangements and Board capability in a manner proportionate to the Company's stage of development and future operating requirements. This will include continued attention to Board composition, internal controls, risk oversight and clear accountability. The Company will also seek to embed appropriate environmental, social and governance considerations and wider corporate responsibility into investment decision-making and, as operating activities develop, into the management of employees, patient welfare, resource use and stakeholder relationships.

5. Build a disciplined and scalable healthcare platform

The Company's longer-term objective is to develop a healthcare and related services platform supported by disciplined capital allocation, effective operating oversight and selective acquisition. The Board expects any future expansion to be informed by the financial capacity, management resources and operating experience established through the initial acquisition. Future opportunities will be assessed by reference to business quality, sustainable cash generation, strategic fit, risk-adjusted returns and their potential contribution to long-term shareholder value.

The Board believes that the work undertaken during the first half, together with continued financing and transaction execution after the period end, has strengthened the Company's ability to progress its strategy. The immediate focus remains disciplined execution of the initial acquisition and AIM Admission, supported by appropriate governance, liquidity and operating readiness.

Beacon Rise Holdings plc is a SPAC (Special Purpose Acquisition Company) currently suspended from the London Stock Exchange, remains committed to identifying and acquiring high-quality target companies with the view to seeking readmission to trading on the London Stock Exchange of the enlarged group.   

The Board of Beacon Rise reaffirms its commitment to disciplined execution, transparent governance, and sustainable value creation. Upon the strong operational and regulatory foundation, we established in the first half of 2026, we will continue to deepen our strategic posture, strengthen leadership, and intend to pursue high-quality acquisition targets in education, technology, content, and healthcare in H2 2026.

Following careful discussions by the Board, we have identified the following key areas and directions for our future strategic developments:

1.  Ongoing Compliance and M&A Regulatory Alignment

As a SPAC, the Company will continue to maintain strict regulatory compliance for all acquisition activities, ensuring full transparency and adherence to the FCA’s and LSE’s regulatory regime.

2.  Further Talent Acquisition Across Strategic and Operational Roles

Beacon Rise will continue to recruit professionals with expertise in education, health innovation, content technology, and financial governance to strengthen strategic decision-making and post-acquisition integration.

3.  Completion of Governance and Articles Revision

The updated Articles of Association will enhance Board stability, improve risk controls, and strengthen shareholder protections. This legal and structural refinement positions the Company more favourably for future expansion and public listings.

4.  Exploration of Further Equity Financing Opportunities

Following the success of the previous capital raise, the Company will monitor market conditions and investor appetite for further equity financing to support strategic objectives.

5.  High-Potential M&A in Priority Sectors

Beacon Rise will prioritise acquisitions in higher education, vocational training, educational platforms, digital learning content, scientific health education, and premium healthcare services. Target evaluation will emphasise strategic synergy, scalability, and long-term impact.

With the continuous governance refinement, resource expansion, and alignment with long-term market trends, we aim to position the Company as a leading platform for innovation, collaboration, and sustainable performance within the evolving education and healthcare landscape. We commit to all stakeholders that we will contribute to the following areas in a continuous way:

1.   Expanding Acquisition Scope

·      Sector-Focused Acquisition Strategy:

While we will explore opportunities across various sectors, our primary focus will remain on AI, emerging service industries, and educational technology. Our goal is to find a high-growth potential acquisition target that meets the regulatory framework governing UK quoted companies. We will pursue horizontal acquisitions and vertical integrations to achieve business synergy and resource optimisation.

The emphasis will be on identifying firms that can rapidly expand in the market and hold significant competitive advantages.

·      Business Combination Execution:

To enhance the effectiveness of any business combination, we will streamline acquisition processes and strategies, ensuring the quality and suitability of any target companies. Ultimately, we will focus on a single vertical segment, identifying a high-growth potential company that meets the regulatory framework governing UK quoted companies. Any such strategic acquisition, led directly by the Board, is intended to enhance our market position and business capabilities.

2.   Maximising Shareholder Value and Interests

·      Transparency and Responsibility:

We are committed to maximising shareholder value through transparent and responsible management. We will maintain clear communication with investors, providing timely updates on strategic and operational developments to build trust and support. We will ensure that shareholders are well-informed about our development plans and strategic direction, thereby increasing investor confidence and support.

·      Investor Relations:

Strengthening communication and interaction with investors is key. We will utilise investor relations management systems and hold regular investor meetings to convey our vision, strategy, and performance, thus improving investor relations management. Investors will be reminded to consider the FCA regulations effective from 29 July 2024 and make informed judgments about our future opportunities and challenges.

·      Operational Security and Quality

Funds Management: Ensuring sufficient operational funds is crucial. We have employed meticulous funds management and risk control practices to maintain stability amidst market fluctuations and uncertainties. Diversified financing channels, including equity financing, debt financing, and internal cash flow, will be used to ensure adequate and stable funding. We aim to ensure that we have the necessary financial resources to pursue our strategic objectives without facing liquidity issues.

·      Compliance Operations:

As a SPAC (Special Purpose Acquisition Company), we strictly adhere to all relevant rules to ensure legal and compliant operational activities. Regular internal audits and risk assessments are conducted to identify and mitigate potential issues, ensuring transparent and standardised operations. We have established a compliance management system, including compliance training, monitoring, and reporting, to ensure operational legality and compliance.

3.   Emphasising Sustainable Development

·      Sustainable Development Strategy:

We are committed to sustainable development, emphasising low-efficiency energy use and environmental conservation. We will develop and implement a sustainable development strategy to ensure long-term business health. Sustainable development indicators (e.g., Environmental, Social and Governance ("ESG")) will be used to evaluate and enhance our sustainability performance. We will publish sustainable development reports to disclose our sustainability performance and achievements to shareholders and the public. We aim to integrate sustainable practices into our business model, ensuring that growth is achieved responsibly.

·      Green Operating Philosophy:

We emphasise efficient resource utilisation and environmental protection and are committed to minimising our environmental impact.

4.   Corporate Social Responsibility

·      Fulfilling Social Responsibility:

We are actively fulfilling our social responsibilities by supporting community development, environmental projects, and educational initiatives. A social responsibility reporting mechanism will be established to regularly disclose our social responsibility efforts. We will continue to enhance environmental protection, resource conservation, and green operations, promoting sustainable development. We aim to be responsible corporate citizens, contributing positively to society.

Risks and uncertainties

The Company has yet to complete an investment or acquisition, and accordingly it has limited trading history. As such, the Company continued to be subject to the risks and uncertainties associated with an early-stage acquisition company.

The Directors are of the opinion that these risks, which were detailed in the published results for the financial period ended 31 December 2025, remain applicable to the Company.

Dividend

At this point of the Company's development, it does not anticipate declaring any dividends in the foreseeable future. Following the Company's inaugural investment or acquisition, the Directors will determine an appropriate dividend policy.

Looking forward, the Company will strictly enforce corporate governance and further strengthen the leadership of the Board of Directors over the Company. We have been actively looking for acquisition targets that can create long-term value for all shareholders and meanwhile we continue to be confident in our potential acquisition opportunities even if the volatility in capital markets continues to cause challenges across the markets.

I would like to take this opportunity to thank the shareholders for their continued support as we build Beacon Rise into a significant organisation.

The Interim Report and directors' responsibility statement were approved by the Board of Directors on 28 September 2026.

John Parker

Chairman

Directors' responsibilities statement

The Directors confirm, to the best of their knowledge, that these unaudited condensed interim financial statements:

·      have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting';

·      gives a true and fair view of the assets, liabilities, financial position and profit/loss of the Company;

·      includes a fair review of the information required by DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the set of interim financial statements, and a description of the principal risks and uncertainties for the remaining six months of the year; and

·      includes a fair review of the information required by DTR 4.2.8R of the Disclosure and Transparency Rules, being the information required on related party transactions.

					6 months ended 30 June 2026	6 months ended 30 June 2025
			Note		(Unaudited)	(Unaudited)
					£	£
Administrative expenses					(1,240,895)	(134,792)
Loss from operations Interest receivable					(1,240,895) 7	(134,792) -
Loss before taxation					(1,240,888)	(134,792)
Taxation on loss of ordinary activities					-	-
Loss for the period from continuing operations					(1,240,888)	(134,792)
Other comprehensive income					-	-
Total comprehensive loss for the period attributable to shareholders					1,240,888)	(134,792)
Earnings per share (basic and dilutive)				6	(0.81)	(0.11)

The statement of comprehensive income has been prepared on the basis that all operations are continuing operations. The notes on page 12 - 16 form an integral part of the condensed interim financial statements.

		30 June 2026 (Unaudited)	31 December 2025 (Audited)
Note		£	£
Assets
Current assets
Non-current assets  Property and Equipment		3,320	4,065
Current Assets
Other receivables		78,875	56,325
Cash and cash equivalents		32,965	72,529
Total current assets		111,840	128,854
Total assets		115,160	132,919
Liabilities
Current liabilities
Trade and other liabilities		763,506	140,377
Total current liabilities		763,506	140,377
Total liabilities		763,506	140,377
Net liabilities		(648,346)	(7,458)

Issued capital and reserves
Share capital	7	1,550,333	1,411,482
Share premium		221,667	138,356
Shares to be issued		600,000	222,162
Retained earnings		(3,020,346)	(1,779,458)
Total deficit		(648,346)	(7,458)

STATEMENT OF CHANGES IN EQUITY

FOR THE INTERIM PERIOD ENDED 30 JUNE 2026

Unaudited	Share capital	Shares to be issued	Share premium	Retained earnings	Total equity
	£	£	£	£	£
Balance at 1 January 2025	1,180,333	-	11,667	(1,085,397)	106,603
Loss for the period	-	-	-	(134,792)	(134,792)
Total comprehensive loss for the period	-	-	-	(134,792)	(134,792)
Contributions by and distributions to owners
Issue of share capital	120,000	-	60,000	-	180,000
Transactions with owners in own capacity	120,000	-	60,000	-	180,000
Balance at 30 June 2025	1,300,333	-	71,667	(1,220,189)	151,811

Unaudited	Share capital	Shares to be issued	Share Premium	Retained earnings	Total equity
	£	£	£	£	£
Balance at 1 January 2026	1,411,482	222,162	138,356	(1,779,458)	(7,458)
Loss for the period	-	-	-	(1,240,888)	(1,240,888)
Total comprehensive loss for the period	-	-	-	(1,240,888)	(1,240,888)
Contributions by and distributions to owners
Issue of share capital	138,851	(222,162)	83,311	-	-
Shares to be issued	-	600,000	-	-	600,000
Transactions with owners in own capacity	138,851	377,838	83,311	-	600,000
Balance at 30 June 2026	1,550,333	600,000	221,667	(3,020,346)	(648,346)

					6 months ended 30 June		6 months ended 30 June
					2026		2025
					(Unaudited)		(Unaudited)
					£		£
Cash flows from operating activities
Loss for the period					(1,240,888)		(134,792)
Depreciation of property and equipment					745		-
Changes in working capital:
Increase in trade and other receivables					(22,550)		(14,800)
Increase/(decrease) in trade and other payables					623,129		(16,589)
Net cash used in operating activities					(639,564)		(166,181)
Cash flows from financing activities
Proceeds from issue of shares						-	180,000
Proceeds from shares to be issued						600,000	-
Net cash flow from financing activities						600,000	180,000
Net (decrease)/increase in cash and cash equivalents						(39,564)	13,819
Cash and cash equivalents at the beginning of period					72,529		150,134
Cash and cash equivalents at the end of the period					32,965		163,953

1.       Accounting policies

The interim financial statements have not been audited or reviewed and do not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The figures have been prepared using applicable accounting policies and practices consistent with those adopted in the audited annual financial statements for the year ended 31 December 2025.

Going concern

The Company's condensed interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue to meet its liabilities as they fall due.
The Directors review the Company's financial forecast against the quarterly management accounts to assess the Company's working capital requirement. The Company has sufficient cash at bank of £32,965 to meet its forecasted liabilities based on committed cash out flows and the Company will carry out further fundraising when suitable acquisition targets are found.

It is on these considerations that the Directors have a reasonable expectation that the Company has sufficient funds and adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

2.	Reporting entity

Beacon Rise Holdings Plc (the 'Company') is a limited company incorporated in the United Kingdom. The Company's registered office is at Room 639, 6^th Floor 2 Kingdom Street, London, United Kingdom, W2 6BD. The Company's principal activity is being an investment vehicle and its principal activity is to seek acquisition in the primary and secondary segments of the education technology sectors.

3.	Basis of preparation

These condensed interim financial statements have been prepared in accordance with International Accounting Standard ('IAS') 34 - Interim Financial Reporting. The condensed interim financial statements are for the six months to 30 June 2026, being six months from the financial year end for the Company being 31 December 2025. The interim financial statements do not include all of the information or disclosures required in the annual financial statements and should be read in conjunction with the Company's audited financial statements for the year ended 31 December 2025.
The condensed interim financial statements have not been audited. The condensed interim financial statements do not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The figures have been prepared using applicable accounting policies and practices consistent with those adopted in the audited financial statements which have been delivered to the Registrar of Companies and contained an unqualified audit report. for the year ended 31 December 2025.
In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of the Company's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.
Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

The areas where judgments and estimates have been made in preparing the financial statements and their effects are disclosed in note 5.

The interim financial information contained in this document does not constitute statutory accounts. In the opinion of the Directors, the financial information for this period fairly presents the financial position, result of operations and cash flows for this period.

3.1 Basis of measurement
The financial statements have been prepared on the historical cost basis.

3.2 Changes in accounting policies
   New standards, interpretations, and amendments adopted by the Company

During the current period the Company adopted all the new and revised standards, interpretations, and amendments that are relevant to its operations and are effective for accounting periods beginning on 1 January 2026. This adoption did not have a material effect on the accounting policies of the Company.

New standards, interpretations, and amendments not yet effective

Standards	Impact on initial application	Effective date
IFRS 19	Subsidiaries without public accountability: disclosures	1 January 2027
IFRS 18	Presentation and disclosure in Financial Statements	1 January 2027
IAS 21	Translation to a Hyperinflationary Presentation Currency (Amendments to IAS 21)	1 January 2027
IFRS 20	IFRS 20 Regulatory Assets and Regulatory Liabilities	1 January 2029

The Directors are evaluating the impact that these standards may have on the financial statements of the Company. The effect of these new and amended Standards and Interpretations which are in issue but not yet mandatorily effective is not expected to be material.

3.3 Segmental analysis

The Company manages its operations in one segment, seeking a suitable investment in the primary and secondary segments of the education technology sectors. The results of this segment are regularly reviewed by the Board as a basis for the allocation of resources, in conjunction with individual investment appraisals, and to assess its performance.

4.	Functional and presentational currency

These financial statements are presented in pound sterling, which is the Company's functional currency. All amounts have been rounded to the nearest pound unless otherwise indicated.

5.	Accounting estimates and judgments

The Company makes estimates and assumptions regarding the future. Estimates and judgements are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual results may differ from these estimates and assumptions. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period.

6.	Earnings per share
					6 months ended 30 June	6 months ended 30 June
					2026	2025
					(Unaudited)	(Unaudited)
					£	£
	Loss attributable to shareholders of Beacon Rise Holdings Plc				(1,240,888)	(134,792)
	Weighted number of ordinary shares in issue				1,550,333	1,225,416
	Basic & dilutive earnings per share from continuing operations				(0.81)	(0.11)

7.    Share capital       Authorised
				30 June				30 June	31 December		31 December
				2026 (Unaudited)				2026 (Unaudited)	2025 (Audited)		2025 (Audited)
				Number				£	Number		£
Share Capital
Ordinary shares of £1.00 each				1,550,333				1,550,333	1,411,482		1,411,482
				1,550,333				1,550,333	1,411,482		1,411,482
Issued
	30 June 2026		30 June 2026			30 June 2026		31 December 2025	31 December 2025		31 December 2025
			Share capital			Share premium			Share capital		Share premium
	Number		£			£		Number	£		£
Ordinary shares of £1.00 each
Issue of ordinary shares on incorporation - note (a)		1	1			-		1	1		-
Issue of ordinary shares - note (b)		49,999	49,999			-		49,999	49,999		-
Issue of ordinary shares - note (c)		1,037,000	1,037,000			-		1,037,000	1,037,000		-
Issue of ordinary shares - note (d)		35,000	35,000			-		35,000	35,000		-
Issue of ordinary shares - note (e)		58,333	58,333			11,667		58,333	58,333		11,667
Issue of ordinary shares - note (f)		120,000	120,000			60,000		120,000	120,000		60,000
Issue of ordinary shares - note (g)		111,149	111,149			66,689		111,149	111,149		66,689
Issue of ordinary shares - note (h)		138,851	138,851			83,311		-	-		-
		1,550,333	1,550,333			221,667		1,411,482	1,411,482		138,356
(a)  On incorporation on 14 September 2021, the Company issued 1 ordinary share at their nominal value of £1. (b)  On 11 November 2021, the Company issued 49,999 ordinary shares at their nominal value of £1.00. (c)  On admission to the Standard List of the LSE on 25 March 2022, the Company issued 1,037,000 ordinary shares at their nominal value of £1.00. (d)  On 27 June 2022, the Company issued 35,000 ordinary shares at their nominal value of £1.00. (e)  On 14 February 2024, the Company issued 58,333 ordinary shares at the value of £1.20. (f)   On 24 April 2025, the Company issued 120,000 ordinary shares at the value of £1.50. (g)  On 26 September 2025, the Company issued 111,149 ordinary shares at £1.60. (h)  On 19 January 2026, the Company issued 138,851 ordinary shares at £1.60. 8. Related party transactions During the period, £111,334 (6 months ended 30 June 2025 (unaudited): £47,500) directors' remuneration was incurred. Other than these there were no other related party transactions. 9. Ultimate Controlling Party The ultimate controlling party is Xiaobing Wang. 10. Capital management The Company considers its capital to be equal to the sum of its total equity. The Company monitors its capital using a number of key performance indicators including working capital ratios. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure. The Company funds its capital requirements through the issue of new shares to investors. 11. Events subsequent to period end           There were no material events subsequent to period end that require disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.